Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-029-3 | CAS number: 77-47-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
The carcinogenicity of Hexachlorocyclopentadiene was evaluated using a method similar to the OECD Test Guideline 453 (GLP). Rats were exposed at concentrations of 0, 0.01, 0.05 or 0.2 ppm of Hexachlorocyclopentadiene in air (equivalent to 0, 0.11, 0.56 and 2.28 mg/m3) for 6 hours per day, 5 days per week, for 103 to 104 weeks. No animals died as a result of the exposure to Hexachlorocyclopentadiene. Observation were made of granular pigment in a few cells in bronchi and branchioles of the lung of exposed rats as well as in a small number of control animals. In female rats exposed at 0.01 and 0.2 ppm of test substance, significant incidences of squamous metaplasia of the larynx were observed.
Specific gravity measurements of urine from males exposed to 0.01, 0.05, and 0.2 ppm and from females exposed to 0.05 and 0.2 ppm of test substance were significantly greater than those from the controls. Urine volume of females in the 0.2 ppm group was significantly lower than that of the controls. These differences suggest a treatment-related renal disorder, but the lack of chemical-related kidney lesions does not support such as conclusion.
This carcinogenicity study by inhalation allowed to determine a NOAEC above 0.2 ppm (equivalent to 2.28 mg/m3) for both the systemic effects and a LOAEC of 0.01 ppm (equivalent to 0.11 mg/m3) for the local effects based on findings in the respiratory tract. No neoplastic effects were observed that could be attributed to the exposure to Hexachlorocyclopentadiene. It was concluded that the substance was not a carcinogen under the conditions of the study.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Link to relevant study records
- Endpoint:
- carcinogenicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 2 December 1985 to 4 December 1987
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- yes
- Remarks:
- Ophthalmological examination, haematology, urinalysis, and biochemistry were not included. Temperature and humidity were outside the ranges.
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Frederick Cancer Research Facility
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 6-7 weeks
- Weight at study initiation: Females: 110 to 112g / Males: 139 to 143g
- Housing: individually in stainless steel cages (Hazleton Systems)
- Diet (e.g. ad libitum): NIH-07 pelleted rodent diet ad libitum
- Water (e.g. ad libitum): Tap water ad libitum
- Acclimation period: 19 days
DETAILS OF FOOD AND WATER QUALITY:
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C-29°C
- Humidity (%): 21%-88%
- Air changes (per hr): 9-20 changes/h
- Photoperiod (hrs dark / hrs light): 12h/12h - Route of administration:
- inhalation: vapour
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Stainless steel whole-body inhalation chamber (Hazleton Systems)
- Source and rate of air: fresh air
- System of generating particulates/aerosols: Vaporizer. Gardner Type CN condensation nuclei detector
used to ensure the generation of vapour and not of aerosol.
TEST ATMOSPHERE
- Brief description of analytical method used: On-line gas chromatograph with electron capture detector.
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- A gas chromatograph with an electron capture detector was used. The system was a 3% OV-225 coating on a 100/120 mesh Gas Chrom Q column and an argon/methane (9O:lO) carrier gas at a flow rate of 30 mL/minute. Column was maintained isothermally at 125°C.
- Duration of treatment / exposure:
- 103 to 104 weeks
- Frequency of treatment:
- 6 hours per day, 5 days per week
- Dose / conc.:
- 0 ppm (nominal)
- Remarks:
- Equivalent to 0 mg/m3.
- Dose / conc.:
- 0.01 ppm (nominal)
- Remarks:
- Equivalent to 0.11 mg/m3.
- Dose / conc.:
- 0.05 ppm (nominal)
- Remarks:
- Equivalent to 0.56 mg/m3.
- Dose / conc.:
- 0.2 ppm (nominal)
- Remarks:
- Equivalent to 2.28 mg/m3.
- No. of animals per sex per dose:
- 60 animals/sex/dose.
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Based on results of a 13-week repeated dose toxicity study by inhalation performed beforehand
- Rationale for animal assignment (if not random): XYBION PATH/TOX System - Positive control:
- No
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Every 4 weeks
BODY WEIGHT: Yes
- Time schedule for examinations: Initially, weekly for the first 13 weeks, then monthly.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: Yes
- Time schedule for collection of urine: 15 months
- Metabolism cages used for collection of urine: Yes
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Statistical analyses for possible dose-related effects on survival used Cox’s (1972) method for testing two groups for equality and Tarone’s (1975) life table test to identify dose-related trends.
The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958). - Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Only urinalysis was performed at 15 months. Specific gravity measurements of urine from males exposed to 0.01, 0.05, and 0.2 ppm and from females exposed to 0.05 and 0.2 ppm of test substance were significantly greater than those from the controls. Urine volume of females in the 0.2 ppm group was significantly lower than that of the controls.
These differences suggest a treatment-related renal disorder, but the lack of chemical-related kidney lesions does not support such as conclusion. - Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In male rats exposed to 0.05 and 0.2 ppm of test substance, absolute lung weight was significantly lower than those of the controls but not the relative lung weight, therefore it was concluded that it was related to the lower body weights rather than to the treatment.
- Description (incidence and severity):
- Accumulation of granular pigment in nose, trachea, and bronchi and branchioles of the lung.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Observation of granular pigment in a few cells in bronchi and branchioles of the lung of exposed rats as well as in a small number of control animals.
In female rats exposed at 0.01 and 0.2 ppm of test substance, significant incidences of squamous metaplasia of the larynx was observed. This effect was not investigated in male rats. - Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Significant increased incidence of pars distalis adenoma in pituitary gland was observed in male rats exposed at 0.2 ppm of test substance but was similar to the historical control and not considered to be treatment related.
- Relevance of carcinogenic effects / potential:
- No neoplastic effects were observed that could be attributed to the exposure to Hexachlorocyclopentadiene. It was concluded that the substance was not a carcinogen under the conditions of the study.
- Key result
- Dose descriptor:
- NOAEC
- Remarks:
- systemic effects
- Effect level:
- > 2.28 mg/m³ air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- gross pathology
- histopathology: neoplastic
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- Key result
- Dose descriptor:
- LOAEC
- Remarks:
- local effects
- Effect level:
- 0.11 mg/m³ air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- gross pathology
- histopathology: non-neoplastic
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 0.01 ppm
- System:
- respiratory system: upper respiratory tract
- Organ:
- larynx
- nasal cavity
- trachea
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 0.01 ppm
- System:
- respiratory system: lower respiratory tract
- Organ:
- bronchi
- bronchioles
- Conclusions:
- A carcinogenicity/chronic study by inhalation was performed on rats using Hexachlorocyclopentadiene that allowed to determine a NOAEC above 0.2 ppm (equivalent to 2.28 mg/m3) for the systemic effects and a LOAEC of 0.01 ppm (equivalent to 0.11 mg/m3) for the local effects based on findings in the respiratory tract. No neoplastic effects were observed that could be attributed to the exposure to Hexachlorocyclopentadiene. It was concluded that the substance was not a carcinogen under the conditions of the study.
- Executive summary:
The carcinogenicity of Hexachlorocyclopentadiene was evaluated using a method similar to the OECD Test Guideline 453 (GLP) with deviations.
Rats were exposed at concentrations of 0, 0.01, 0.05 and 0.2 ppm of Hexachlorocyclopentadiene in air (equivalent to 0, 0.11, 0.56 and 2.28 mg/m3) for 6 hours per day, 5 days per week, for 103 to 104 weeks. Mortality, clinical signs and body weight were recorded. Urinalysis was investigated once at 15 months. At the end of the study, surviving animals were subjected to gross necropsy and histopathology.
No animals died as a result of the exposure to Hexachlorocyclopentadiene. Observation were made of granular pigment in a few cells in bronchi and branchioles of the lung of exposed rats as well as in a small number of control animals. In female rats exposed at 0.01 and 0.2 ppm of test substance, significant incidences of squamous metaplasia of the larynx were observed. This effect was not investigated in male rats.
Significant increased incidence of pars distalis adenoma in pituitary gland was observed in male rats exposed at 0.2 ppm of test substance but was similar to the historical control and not considered to be treatment related.
In male rats exposed to 0.05 and 0.2 ppm of test substance, absolute lung weight was significantly lower than those of the controls but not the relative lung weight, therefore it was concluded that it was related to the lower body weights rather than to the treatment.
Specific gravity measurements of urine from males exposed to 0.01, 0.05, and 0.2 ppm and from females exposed to 0.05 and 0.2 ppm of test substance were significantly greater than those from the controls. Urine volume of females in the 0.2 ppm group was significantly lower than that of the controls. These differences suggest a treatment-related renal disorder, but the lack of chemical-related kidney lesions does not support such as conclusion.
This carcinogenicity study by inhalation allowed to determine a NOAEC above 0.2 ppm (equivalent to 2.28 mg/m3) for both the systemic effects and a LOAEC of 0.01 ppm (equivalent to 0.11 mg/m3) for the local effects based on findings in the respiratory tract. No neoplastic effects were observed that could be attributed to the exposure to Hexachlorocyclopentadiene. It was concluded that the substance was not a carcinogen under the conditions of the study.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 2.28 mg/m³
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- The carcinogenicity of Hexachlorocyclopentadiene was evaluated using a method similar to the OECD Test Guideline 453 (GLP) with non-significant deviations.
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
A carcinogenicity/chronic study by inhalation was performed on rats using Hexachlorocyclopentadiene that allowed to determine a NOAEC above 0.2 ppm (equivalent to 2.28 mg/m3) for the systemic effects and a LOAEC of 0.01 ppm (equivalent to 0.11 mg/m3) for the local effects based on findings in the respiratory tract. No neoplastic effects were observed that could be attributed to the exposure of Hexachlorocyclopentadiene. It was concluded that the substance was not a carcinogen under the conditions of the study. It did not meet the criteria for classification according to Regulation (EC) N° 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.